When you begin to look at hormones through the lens of methylation, the conversation changes very quickly. MTHFR is not a standalone gene, it sits within an interconnected methylation system that governs how the body processes hormones, regulates neurotransmitters, and maintains stability within the nervous system. When that system is less efficient, the handling of oestrogen and progesterone is directly affected.

Oestrogen is not simply a hormone that rises and falls. It is continuously being metabolised through specific liver pathways, converted into intermediate metabolites, and then cleared via methylation. This process relies heavily on nutrients, enzyme function, and genetic efficiency. When methylation is compromised, oestrogen is more likely to accumulate or be pushed down less favourable pathways, particularly towards metabolites that are more reactive and less easily cleared. This is where symptoms such as breast tenderness, headaches, fluid retention, mood volatility, and a sense of internal pressure begin to emerge. The system is not lacking oestrogen, it is struggling to process it.

Progesterone, by contrast, exerts a stabilising influence, particularly on the nervous system through its interaction with GABA. It helps to modulate excitatory signalling and allows the system to settle. When oestrogen clearance is inefficient, the relative balance shifts, even if progesterone levels are unchanged. The result is often heightened sensitivity, disrupted sleep, irritability, and anxiety that feels distinctly hormonal. In individuals who already have a responsive or sensitised nervous system, this imbalance is amplified.

When HRT is introduced into this context, the question is not whether hormones are needed, but whether the system has the capacity to process them. This is where I often see significant issues in practice. External oestrogen increases the demand on methylation and detoxification pathways that may already be under strain. One of the most important genes here is COMT. COMT is responsible for methylating catecholamines and plays a central role in clearing oestrogen metabolites. When COMT activity is reduced, both neurotransmitters and oestrogen metabolites are broken down more slowly. This leads to prolonged biological activity, increased stimulation of oestrogen receptors, and a cumulative load on the nervous system.

In practical terms, this can present as anxiety that escalates rather than settles, poor sleep, heightened emotional reactivity, breast symptoms, migraines, and a sense that the system is overloaded. This is not uncommon. It is a predictable outcome when additional oestrogen is introduced into a system that already has reduced clearance capacity.

This pattern is rarely isolated. Variants in MTHFR can reduce the availability of methyl-folate, which is required to drive methylation forward. Variants in MTR and MTRR can affect B12 recycling, further limiting methylation efficiency. BHMT may be downregulated, reducing the effectiveness of the alternative pathway for recycling homocysteine. In the transsulphuration pathway, increased CBS activity can divert homocysteine away from methylation, while reduced glutathione production limits the body’s ability to neutralise oxidative byproducts generated during hormone metabolism. When these patterns combine, the system becomes less resilient, less able to clear hormones efficiently, and more reactive to additional load.

This is why a standardised approach to HRT does not work for everyone. It assumes that all systems have equal capacity to metabolise and clear hormones, which is not the case. In my practice, I use genetic testing to understand how each individual is likely to process hormones at a biochemical level. MTHFR is part of that, but it is the interaction with COMT, the wider methylation cycle, and detoxification pathways that provides the real insight.

The work then becomes specific. Supporting methylation through appropriate forms of folate, B12, B6, and riboflavin can improve the efficiency of these pathways. Supporting glutathione production enhances the body’s ability to manage oxidative stress generated during hormone metabolism. Ensuring adequate mineral status supports enzyme function across the system. At the same time, reducing inflammatory load and stabilising the nervous system changes how these pathways are experienced day to day.

Hormones do not operate in isolation from the nervous system. A system that is already in a heightened state of alert will respond differently to hormonal shifts than one that has the capacity to regulate and settle. This is often why symptoms are not only cyclical, but also closely linked to stress, life events, and overall physiological load.

When I work in this way, genetics provide a map of how the system is likely to behave under pressure. They help explain why some individuals tolerate HRT well, while others experience increased symptoms. They also highlight where support is needed before introducing additional hormonal load.

This is not about rejecting HRT. It is about recognising that without adequate methylation and detoxification capacity, and without a regulated nervous system, adding hormones can increase pressure on an already burdened system. When those underlying pathways are supported first, the response to hormones, whether endogenous or introduced, becomes far more stable and predictable.

This is the space I work in. Bringing together nervous system regulation, genetic insight, and clinical experience, I work with systems that are complex and often highly sensitive. When those systems are understood at the level of their underlying pathways, the body begins to respond differently. Hormones become less chaotic, the nervous system more settled, and the overall experience far more manageable.